# US 2011/0300209 A1 · Modified release solid pharmaceutical compositions of trimetazidine and process thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300209 A1
- Document ID: US20110300209A1
- Status: Published application
- Kind: A1
- Application number: 13/145,237
- Filed: 2010-01-18
- Published: 2011-12-08
- Earliest claimed: 2009-01-20
- Assignees: Micro Labs Limited
- Inventors: Pradeep G. Surve; Pankaj S. Mandpe; Unmesh H. Chavan; Jaideep T. Patil; Animesh S. Salunkhe
- Web page: https://patentgrep.com/patent/US20110300209A1

## CPC

- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.

## Claims

### Claim 1

A modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.

### Claim 2 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the composition is in the form of one or more of tablet, capsule, powder, disc, caplet, granules, pellets, granules in capsule, minitablets, minitablets in capsule, pellets in capsule or sachet.

### Claim 3 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the composition is in the form of tablet.

### Claim 4 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the composition is in the form of capsule.

### Claim 5 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the polyethylene oxide is having a viscosity in the range of 5,000 and 10,000 in 1% solution.

### Claim 6 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the polyethylene oxide is present within 30% to 60% of the total weight of the composition.

### Claim 7 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the composition comprises one or more of pharmaceutically acceptable inert excipients.

### Claim 8 (depends on 7)

The solid pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable inert excipients comprise one or more of fillers, binders and disintegrant.

### Claim 9 (depends on 8)

The solid pharmaceutical composition of claim 8, wherein the fillers comprise one or more of microcrystalline cellulose, calcium phosphate, calcium sulfate, kaolin, starch, powdered sugar.

### Claim 10 (depends on 8)

The solid pharmaceutical composition of claim 8, wherein the binders comprise one or more of povidone, starch, gums, hydroxypropylmethyl cellulose.

### Claim 11 (depends on 8)

The solid pharmaceutical composition of claim 8, wherein the disintegrants comprise one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate.

### Claim 12 (depends on 1)

The solid pharmaceutical composition of claim 1, wherein the composition comprises a coating.

### Claim 13 (depends on 12)

The solid pharmaceutical composition of claim 12, wherein the coating is functional coating.

### Claim 14 (depends on 13)

The solid pharmaceutical composition of claim 13, wherein the coating comprises modified release polymers.

### Claim 15 (depends on 14)

The solid pharmaceutical composition of claim 14, wherein the modified release polymer comprise one or more of water soluble polymer and water insoluble polymer.

### Claim 16 (depends on 14)

The solid pharmaceutical composition of claim 14, wherein the modified release polymers comprise a combination of water soluble polymer and water insoluble polymer.

### Claim 17 (depends on 16)

The solid pharmaceutical composition of claim 16, wherein the ratio of water soluble polymer and water insoluble polymer is from 1:5 to 5:1.

### Claim 18 (depends on 12)

The solid pharmaceutical composition of claim 12, wherein the coating further comprises pharmaceutically acceptable inert excipients.

### Claim 19

A process for the preparation modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant, the process comprising the steps of:
(a) granulating Trimetazidine optionally with pharmaceutically acceptable inert excipients to form granules;
(b) drying the granules;
(c) mixing the dried granules with polyethylene oxide to form a blend; and
(d) compressing the blend into suitable sized tablet;
(e) optionally coating the tablet.

### Claim 20 (depends on 19)

The process of claim 19, wherein the process comprises wet granulation process.
